Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas

NCT02763254 is registered in ClinicalTrials.gov with Cell Medica Ltd as lead sponsor.

NCT NCT02763254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02763254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas
Lead sponsor
Cell Medica Ltd
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2016
Completion date
February 17, 2018
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma, lymphoma, large b-cell, diffuse, post-transplant lymphoproliferative disorder